Long-term outcome of adipose-derived regenerative cell-enriched autologous fat transplantation for reconstruction after breast-conserving surgery for Japanese women with breast cancer
- 353 Downloads
More effective methods are needed for breast reconstruction after breast-conserving surgery for breast cancer. The aim of this clinical study was to assess the perioperative and long-term outcomes of adipose-derived regenerative cell (ADRC)-enriched autologous fat grafting.
Ten female patients who had undergone breast-conserving surgery and adjuvant radiotherapy for breast cancer were enrolled. An ADRC-enriched fat graft prepared from the patient’s adipose tissue was implanted at the time of adipose tissue harvest. The perioperative and long-term outcomes of the grafts, which included safety, efficacy, and questionnaire-based patient satisfaction, were investigated.
The mean operation time was 188 ± 30 min, and the mean duration of postoperative hospitalization was 1.2 ± 0.4 days. No serious postoperative complications were associated with the procedure. Neither recurrence nor metastatic disease was observed during the follow-up period (7.8 ± 1.5 years) after transplantation. Of 9 available patients, “more than or equal to average” satisfaction with breast appearance and overall satisfaction were reported by 6 (66.7%) and 5 (55.6%) patients, respectively.
ADRC-enriched autologous fat transplantation is thus considered to be safe perioperatively, with no long-term recurrence, for patients with breast cancer treated by breast-conserving surgery, and it may be an option for breast reconstruction, even after adjuvant radiotherapy.
KeywordsBreast cancer Breast-conserving surgery Breast reconstruction Adipose-derived regenerative cell Quality of life
Compliance with ethical standards
Conflict of interest
Mark H. Hedrick is the President and Chief Executive Officer of Cytori Therapeutics, Inc. Hideki Iwaguro is the Director of Medical and Scientific Affairs of Cytori Therapeutics, K.K. The other authors declare that they have no conflicts of interest in association with this study.
Role of the funding source
The Celution system was loaned at no charge, and reagents and disposable supplies were provided at no cost for this study by Cytori Therapeutics, Inc.
- 12.Granel B, Daumas A, Jouve E, Harle JR, Nguyen PS, Chabannon C, et al. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis. 2015;74:2175–82.CrossRefPubMedGoogle Scholar
- 13.Houtgraaf JH, den Dekker WK, van Dalen BM, Springeling T, de Jong R, van Geuns RJ, et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59:539–40.CrossRefPubMedGoogle Scholar
- 14.Perin EC, Sanz-Ruiz R, Sanchez PL, Lasso J, Perez-Cano R, Alonso-Farto JC, et al. Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: the PRECISE trial. Am Heart J. 2014;168(88–95):e2.Google Scholar
- 18.Koh KS, Oh TS, Kim H, Chung IW, Lee KW, Lee HB, et al. Clinical application of human adipose tissue-derived mesenchymal stem cells in progressive hemifacial atrophy (Parry-Romberg disease) with microfat grafting techniques using 3-dimensional computed tomography and 3-dimensional camera. Ann Plast Surg. 2012;69:331–7.CrossRefPubMedGoogle Scholar
- 23.Gentile P, Orlandi A, Scioli MG, Di Pasquali C, Bocchini I, Curcio CB, et al. A comparative translational study: the combined use of enhanced stromal vascular fraction and platelet-rich plasma improves fat grafting maintenance in breast reconstruction. Stem Cells Transl Med. 2012;1:341–51.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Sobin LH, Wittekind C. International Union against Cancer. TNM: classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002.Google Scholar
- 27.Sawai S, Nakajima K, Ichihara S, Yano K, Watanabe O, Kitamura K, et al. Cosmetic assessment of the breast after surgery. In: The 12th annual meeting of the Japan Breast Cancer Society. vol 12. 2004. p. 107–8.Google Scholar
- 34.Zimmerlin L, Donnenberg AD, Rubin JP, Basse P, Landreneau RJ, Donnenberg VS. Regenerative therapy and cancer: in vitro and in vivo studies of the interaction between adipose-derived stem cells and breast cancer cells from clinical isolates. Tissue Eng Part A. 2011;17:93–106.CrossRefPubMedGoogle Scholar